Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

MRK

Merck & Co Inc

May 17 • 04:00PM ET

131.19

Dollar change +0.31
Percentage change 0.24	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO IVV VTV VIG VYM VHT IWD DGRO HDV

Scroll to Statements

Index	DJIA, S&P 500	P/E	146.04	EPS (ttm)	0.90	Insider Own	0.12%	Shs Outstand	2.53B	Perf Week	0.87%
Market Cap	332.28B	Forward P/E	13.20	EPS next Y	9.94	Insider Trans	-11.88%	Shs Float	2.53B	Perf Month	4.76%
Income	2.31B	PEG	-	EPS next Q	2.14	Inst Own	79.11%	Short Float	0.74%	Perf Quarter	2.66%
Sales	61.09B	P/S	5.44	EPS this Y	473.14%	Inst Trans	0.64%	Short Ratio	2.28	Perf Half Y	29.44%
Book/sh	15.94	P/B	8.23	EPS next Y	14.80%	ROA	2.16%	Short Interest	18.75M	Perf Year	14.32%
Cash/sh	2.25	P/C	58.18	EPS next 5Y	-	ROE	5.29%	52W Range	99.14 - 133.10	Perf YTD	20.34%
Dividend Est.	3.16 (2.41%)	P/FCF	30.10	EPS past 5Y	-42.70%	ROI	3.22%	52W High	-1.44%	Beta	0.41
Dividend TTM	3.00 (2.29%)	Quick Ratio	0.99	Sales past 5Y	7.72%	Gross Margin	71.63%	52W Low	32.33%	ATR (14)	1.94
Dividend Ex-Date	Mar 14, 2024	Current Ratio	1.25	EPS Y/Y TTM	-82.24%	Oper. Margin	8.23%	RSI (14)	59.75	Volatility	1.34% 1.49%
Employees	72000	Debt/Eq	0.85	Sales Y/Y TTM	7.01%	Profit Margin	3.77%	Recom	1.52	Target Price	144.01
Option/Short	Yes / Yes	LT Debt/Eq	0.77	EPS Q/Q	69.28%	Payout	2065.60%	Rel Volume	0.94	Prev Close	130.88
Sales Surprise	3.75%	EPS Surprise	9.79%	Sales Q/Q	8.38%	Earnings	Apr 25 BMO	Avg Volume	8.22M	Price	131.19
SMA20	1.67%	SMA50	3.33%	SMA200	14.39%	Trades		Volume	7,722,350	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70

Show Previous Ratings

May-17-24 06:00AM	Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches (InvestorPlace)
May-16-24 10:51AM	Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game (Benzinga)
09:35AM	Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)
May-15-24 06:45AM	Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline (Business Wire)
May-14-24 09:25AM	Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility (Zacks)
05:21AM	Loading…
05:21AM	Merck cancels trial of melanoma treatment due to immune-mediated adverse events (Clinical Trials Arena)
May-13-24 01:09PM	Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment (Benzinga)
06:45AM	Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma (Business Wire)
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
06:01AM	The 3 Most Undervalued Healthcare Stocks to Buy in May 2024 (InvestorPlace)
May-09-24 09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
07:05AM	Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy (PR Newswire)
06:45AM	Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent (Business Wire)
May-08-24 09:15AM	Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers (ACCESSWIRE)
08:30AM	Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024 (GlobeNewswire)
06:56AM	Loading…
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
06:45AM	Merck to Participate in the Bank of America Securities 2024 Healthcare Conference (Business Wire)
May-07-24 02:49PM	5 Best S&P 500 Dividend Stocks To Buy Now (Insider Monkey)
May-06-24 02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
10:50AM	5 Best Recession Dividend Stocks To Buy (Insider Monkey)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
May-03-24 09:50AM	Here's Why Merck (MRK) is a Strong Momentum Stock (Zacks)
May-02-24 02:53PM	Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration (Benzinga)
May-01-24 06:52PM	15 Best Places to Retire in Florida That You've Never Heard Of (Insider Monkey)
07:15AM	Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Business Wire)
06:24AM	3 Pharma Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
Apr-30-24 08:44AM	Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 09:00AM	Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults (Business Wire)
Apr-28-24 06:54PM	Dividend Stock Portfolio For Income: Top 5 Stocks (Insider Monkey)
Apr-27-24 09:14AM	5 Best Long Term Low Risk Stocks to Buy (Insider Monkey)
10:59AM	Loading…
Apr-26-24 10:59AM	Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 (MT Newswires)
Apr-25-24 05:54PM	5 Best Growth Stocks To Invest In For the Next 5 Years (Insider Monkey)
04:09PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
03:30PM	Merck (MRK) Q1 2024 Earnings Call Transcript (Motley Fool)
02:29PM	Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook (Benzinga)
12:52PM	Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating (MT Newswires)
12:09PM	Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales (Zacks)
11:42AM	Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma (The Wall Street Journal)
11:34AM	20 Fastest Growing Health Tech Companies in the World (Insider Monkey)
11:23AM	Merck raises 2024 guidance on cancer drug demand (Yahoo Finance Video)
10:54AM	MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:30AM	Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:13AM	Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda (The Wall Street Journal)
09:13AM	Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda (The Wall Street Journal)
07:30AM	Stocks plunge on weaker-than-expected GDP reading: Yahoo Finance (Yahoo Finance Video)
07:04AM	UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda (Reuters)
06:44AM	Merck: Q1 Earnings Snapshot (Associated Press Finance)
06:33AM	Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda (Reuters)
06:30AM	Merck raises 2024 profit forecast on strong cancer, HPV drugs sales (Reuters)
06:30AM	Merck Announces First-Quarter 2024 Financial Results (Business Wire)
Apr-24-24 05:50PM	Alphabet, Microsoft, Southwest earnings: What to watch (Yahoo Finance Video)
Apr-23-24 07:49AM	Here's Why Merck & Co. (MRK) Outperformed in Q1 (Insider Monkey)
Apr-22-24 02:39PM	How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings? (Zacks)
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
09:15AM	Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-21-24 10:49AM	11 Hot Growth Stocks To Buy Right Now (Insider Monkey)
Apr-19-24 07:04AM	Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy (PR Newswire)
Apr-18-24 04:27PM	13 Best Low Volatility Stocks to Buy According to Hedge Funds (Insider Monkey)
10:01AM	Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-17-24 05:50PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
08:00AM	Coming FDA Approvals Could Send These 3 Drug Stocks Soaring (InvestorPlace)
Apr-16-24 03:17PM	3 Dow Stocks to Buy Now: Q2 Edition (InvestorPlace)
Apr-15-24 07:48AM	10 Best Low Volatility ETFs To Buy (Insider Monkey)
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Apr-11-24 05:50PM	Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-08-24 11:38PM	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised) (Zacks)
02:00PM	Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement (InvestorPlace)
Apr-07-24 02:00PM	The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024 (InvestorPlace)
Apr-06-24 08:47PM	10 Best Weight Loss Drug Stocks to Buy Now (Insider Monkey)
Apr-05-24 05:45PM	Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
05:33AM	Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate (Zacks)
Apr-04-24 07:38AM	Merck puts KRAS cancer drug competitor to the test (BioPharma Dive)
06:45AM	Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer (Business Wire)
05:36AM	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Zacks)
Apr-03-24 05:50PM	Merck (MRK) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:00AM	REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Apr-01-24 09:50AM	Why Merck (MRK) is a Top Momentum Stock for the Long-Term (Zacks)
06:45AM	Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 (Business Wire)
Mar-29-24 10:51AM	3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-28-24 05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
09:15AM	How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together (ACCESSWIRE)
06:45AM	European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults (Business Wire)
Mar-27-24 04:36PM	US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight (Reuters)
04:00PM	US STOCKS-Stocks gain, led by Dow as investors look for rate insight (Reuters)
02:58PM	US STOCKS-Dow leads gains on Wall Street as investors await rate clues (Reuters)
12:20PM	US STOCKS-Dow outperforms Wall Street in thin trading week (Reuters)
11:54AM	Merck Stock Hits Record High as FDA Approves Its Cardiovascular Disease Drug (Investopedia)
10:58AM	FDA approves Merck treatment for lung disease, potential path to upside (Yahoo Finance Video)
10:26AM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal)
10:10AM	US STOCKS-Dow leads Wall St higher in lean trading week (Reuters)
09:53AM	Merck Drug for Rare Form of High Blood Pressure Gets US Nod (Bloomberg)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
08:50AM	US STOCKS-Wall St set to open higher as growth stocks recover (Reuters)
08:39AM	Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair (Zacks)
07:36AM	US STOCKS-Futures tick up in thin trading week, Fed commentary in focus (Reuters)
07:36AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-26-24 06:21PM	FDA Approves Mercks WINREVAIR (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) (Business Wire)
05:07PM	Mercks $11.5 Billion Bet on Its Next Big Drug Finally Arrives (The Wall Street Journal)
01:12PM	FDA approves Merck lung disease drug acquired in $11B deal (BioPharma Dive)
09:30AM	Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region (ACCESSWIRE)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09 '23	Sale	102.38	2,081	213,061	18,191	Nov 13 07:36 AM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Nov 08 '23	Sale	105.03	43,823	4,602,668	111,764	Nov 09 09:04 AM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30 '23	Option Exercise	102.82	915	94,080	20,723	Oct 31 11:08 AM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 14 '23	Sale	109.01	4,250	463,292	22,935	Aug 15 04:08 PM
Guindo Chirfi	Chief Marketing Officer	Aug 03 '23	Option Exercise	105.70	36,901	3,900,436	38,342	Aug 04 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 03 '23	Sale	105.49	4,500	474,701	27,185	Aug 04 04:06 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02 '23	Sale	107.37	59	6,335	0	Aug 03 04:08 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02 '23	Sale	107.37	30	3,221	20,569	Aug 03 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience